In this study, the reactivate rate of ROP treated solely with anti-VEGF therapy was 13.0%, the ROP reactivation rates of ranibizumab, aflibercept and conbercept were 10.7%, 10.8% and 20%, which were basically consistent with previous literature reports. The gene discussed is VEGFA; the disease is retinopathy of prematurity.